 Cyclacel Pharmaceuticals, Inc. NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company, a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of a public offering with expected total gross proceeds of approximately 20 million, before 